SEC Form 4 · accession 0001144204-18-007442
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stefan Cross
Director
Period of report
Dec 19, 2017
Accepted (ET)
Feb 12, 2018 · 8:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 19, 2017 | P | 600,000 | $162,660.00 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 19, 2017, Stefan Cross sold 600,000 shares of Common Stock to Mayne Pharma Ventures Pty Ltd.